secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000926617-24-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health appoints Sandra Milligan as President effective April 1, 2024
--------------------------------------------------------------------------------

- Dr. Sandra Milligan appointed President, reporting to CEO Nicole Sandford, effective April 1, 2024.
- Base salary of $400,000; eligible for bonus up to 50% of base salary based on corporate goals.
- Granted stock option for 30,000 shares, vesting 25% per year over four years.
- Severance: 6 months salary and COBRA if terminated without cause after 12 months of employment.
- Over 25 years healthcare experience; previously EVP R&D at Organon, roles at Amgen, Genentech, Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661724000006/0000926617-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661724000006/awh-20240316x8k.htm
  HTML page:      https://secwatch.observer/filing/0000926617-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer